
## John Trachtenberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1741225/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review. European Urology, 2014, 66, 732-751.	1.9	298
2	Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort. European Journal of Cancer, 2014, 50, 1610-1616.	2.8	137
3	Dissecting the Association Between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort. European Urology, 2015, 67, 64-70.	1.9	91
4	Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates. Journal of Urology, 2015, 193, 1519-1524.	0.4	90
5	Combination Finasteride and Flutamide in Advanced Carcinoma of the Prostate: Effective Therapy with Minimal Side Effects. Journal of Urology, 1995, 154, 1642-1646.	0.4	82
6	Obesity Is Associated with Risk of Progression for Low-risk Prostate Cancers Managed Expectantly. European Urology, 2014, 66, 841-848.	1.9	56
7	Staging Pelvic Lymphadenectomy for Localized Carcinoma of the Prostate: A Comparison of 3 Surgical Techniques. Journal of Urology, 1997, 157, 1337-1339.	0.4	45
8	Real-Time MRI-Guided Focused Ultrasound for Focal Therapy of Locally Confined Low-Risk Prostate Cancer: Feasibility and Preliminary Outcomes. American Journal of Roentgenology, 2015, 205, W177-W184.	2.2	44
9	Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance. Journal of Urology, 2017, 197, 75-83.	0.4	39
10	Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy. Urology, 2016, 93, 77-85.	1.0	31
11	Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer – phase 1 trial. European Radiology, 2018, 28, 4281-4287.	4.5	30
12	Obesity Is Associated With Larger Prostate Volume but not With Worse Urinary Symptoms: Analysis of a Large Multiethnic Cohort. Urology, 2014, 83, 81-87.	1.0	22
13	Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression. BJU International, 2005, 95, 6-11.	2.5	20
14	Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors. Oncology Letters, 2017, 14, 390-396.	1.8	19
15	Updated results of a randomized, double-blind, multicenter sham-controlled trial of microwave thermotherapy with the Dornier Urowave in patients with symptomatic benign prostatic hyperplasia. World Journal of Urology, 1998, 16, 102-108.	2.2	18
16	Treatment planning for prostate focal laser ablation in the face of needle placement uncertainty. Medical Physics, 2013, 41, 013301.	3.0	15
17	Dynamic contrast enhanced MRI as a predictor of vascular-targeted photodynamic focal ablation therapy outcome in prostate cancer post failed external beam radiation therapy. Canadian Urological Association Journal, 2014, 8, 708.	0.6	15
18	Elastic registration of prostate MR images based on estimation of deformation states. Medical Image Analysis, 2015, 21, 87-103.	11.6	13

JOHN TRACHTENBERG

#	Article	IF	CITATIONS
19	The Effects of Ketoconazole on Testosterone Production and Normal and Malignant Androgen Dependent Tissues of the Adult Rat. Journal of Urology, 1984, 132, 599-601.	0.4	12
20	Active surveillance in patients with a PSA >10 ng/mL. Canadian Urological Association Journal, 2014, 8, 702.	0.6	12
21	Mechatronic system for in-bore MRI-guided insertion of needles to the prostate: An in vivo needle guidance accuracy study. Journal of Magnetic Resonance Imaging, 2015, 42, 48-55.	3.4	12
22	Concordance between transrectal ultrasound guided biopsy results and radical prostatectomy final pathology: Are we getting better at predicting final pathology?. Canadian Urological Association Journal, 2014, 8, 47.	0.6	11
23	Psychological distress and lifestyle disruption in low-risk prostate cancer patients: Comparison between active surveillance and radical prostatectomy. Journal of Psychosocial Oncology, 2018, 36, 159-174.	1.2	11
24	Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer. British Journal of Radiology, 2022, 95, 20210414.	2.2	11
25	MRI-guided biopsies and minimally invasive therapy for prostate cancer. Indian Journal of Urology, 2015, 31, 209.	0.6	10
26	Health-related quality of life in robotic versus open radical prostatectomy. Canadian Urological Association Journal, 2015, 9, 179.	0.6	9
27	Next-generation prostate cancer risk calculator for primary care physicians. Canadian Urological Association Journal, 2017, 12, E64-70.	0.6	8
28	Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic. Canadian Urological Association Journal, 2014, 8, 783.	0.6	7
29	A consensus on trial design for focal therapy. Nature Reviews Urology, 2014, 11, 190-192.	3.8	7
30	Assessment of Cutaneous Photosensitivity of TOOKAD (WST09) in Preclinical Animal Models and in Patients <sup>¶</sup> . Photochemistry and Photobiology, 2005, 81, 106-113.	2.5	6
31	Human kallikrein-2 gene and protein expression predicts prostate cancer at repeat biopsy. SpringerPlus, 2014, 3, 295.	1.2	6
32	The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy. Canadian Urological Association Journal, 2016, 10, 424.	0.6	6
33	A review of hormonal treatment in advanced prostate cancer. Canadian Journal of Urology, 1997, 4, 61-64.	0.0	3
34	The Impact of the Use of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs on the Risk of Prostate Cancer Detection on Biopsy. Urology, 2014, 84, 1073-1080.	1.0	2
35	Internet information on focal prostate cancer therapy: helpÂor hindrance?. Nature Reviews Urology, 2019, 16, 337-338.	3.8	2
36	Editorial: Androgen Ablation Therapy-Where to Next?. Journal of Urology, 1997, 158, 178-178.	0.4	1

#	Article	IF	CITATIONS
37	An assessment of CME needs of Canadian urologists. Canadian Journal of Urology, 1996, 3, 221-225.	0.0	ο